The financing will support the development of Cullgen's internal pipeline of targeted protein degraders in oncology and other diseases, as well as the company's efforts to discover novel E3 ligands that may be used as part of a targeted protein degrader complex.
Sequoia will also assign a board member to join the Cullgen board.
Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology.
The company's research programmes focus on novel treatment for cancer, inflammatory, and autoimmune diseases.
uSMITE (ubiquitin mediated small molecule induced target elimination) is Cullgen's proprietary targeted protein degradation platform that is used to identify novel degraders that attach to a disease-causing protein and then signal the body's ubiquitin proteasome system to eliminate the protein.
Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we've learned over 47 years.
As "The Entrepreneurs Behind The Entrepreneurs," Sequoia focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology with a privilege of working with more than 500 companies in China over the past 14 years.
Highlight Capital currently manages both RMB and funds with a total AUM of nearly USD1.5 bn. Since the inception in 2014, the firm has invested in over 40 deals.
HC is dedicated to supporting healthcare companies to generate robust and sustained growth prospect, and partnering with entrepreneurs of dedication and the highest standard.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007